Jazz Looks To Label Expansion To Reverse Zepzelca Sales Slump

 
• By Alaric DeArment
  
Jazz Pharmaceuticals
The FDA approved Jazz's Zepzelca combined with Roche's Tecentriq in first-line maintenance of extensive-stage small-cell lung cancer. (Shutterstock)

More from Immuno-oncology

More from Anticancer